DSP107 + azacitidine + venetoclax

DSP107 + azacitidine + venetoclax is an investigational combination therapy being studied primarily for hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). DSP107 is a first-in-class, fully human bispecific fusion protein (developed by KAHR) that combines the extracellular domains of SIRPα and 4-1BBL. DSP107 binds to CD47 on tumor cells, blocking the "don't eat me" signal to phagocytes and activating 4-1BB-mediated co-stimulatory signaling to enhance T-cell mediated anti-tumor immunity, thus boosting both innate and adaptive immune responses[1][2][3]. Azacitidine is a small molecule DNA methyltransferase inhibitor and epigenetic modulator, while venetoclax is a small molecule BCL-2 inhibitor, promoting apoptosis in cancer cells.